Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,204.4
-13.8 (-0.43%)

 

  • STI Straits Times Index
    3,204.4
    -13.8 (-0.43%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,571.6
    -11.5 (-0.72%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,619.1
    -9.7 (-0.04%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,528.2
    -34.1 (-0.96%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,877.4
    -220.9 (-0.76%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,535.1
    -67.1 (-1.02%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 919.9M
  • Value: 538.9M
  • Rise: 88
  • Fall: 184
  • Unch: 479

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Raffles Edu0.080+0.013
Tritech0.028-0.001
Geo Energy Res0.335-0.050
Beverly JCG0.001-
Shen Yao0.003-
Rex Intl0.330-0.020
Jiutian Chemical0.086-0.003
Oceanus0.041+0.001
Hatten Land0.059-0.001
Metal Component0.061-0.001

World Indices

World Indices
Name Last Change
Nasdaq 15,235.8 +0.1
HSI 25,630.8 +2.1
HSCEI 9,073.8 -20.0
Jakarta 6,535.1 -67.1
Nikkei 225 28,872.7 -225.5
SSE Comp 3,527.9 -34.4
Shanghai A 3,697.4 -36.0
Shanghai B 269.5 -6.6
KOSPI 3,030.5 +5.0

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

ELI LILLY AND COMPANY ELI LILLY AND COMPANY
Updated on 27 Oct 2021 (End of trading day)
Last (USD): 250.170 Change: +1.730 High: 254.460 Remarks: -
Change (%): +0.70 Low: 248.320
Open 248.610 Yesterday's Close 248.44
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 3,180,761 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 6.47483 Trailing EPS (USD) e 6.34625 NAV (USD) b 6.7369
PE a 38.637 Trailing PE f 39.420 Price / NAV b 37.1343
Dividend (USD) d 2.960026 Cash In Hand (USD) g 3.3662 Issued & Paid-up Shares c 956,581,000
Dividend Yield (%) d 1.183 Price / Cash In Hand g 74.318 Treasury Shares h 463,000
Market Cap (M) 239,307.869 Enterprise Value (M) 252,770.869
Piotroski F Score 7 Exchange Code LLY Par Value ( $ ) n.a.
52 Weeks Volatility (%) 32.97 Free Float (%) 83.1
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 03 Aug 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 03 May 2021.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ELI LILLY AND COMPANY NYSE 239,307.869 38.637 39.420 37.1343 1.183
Industry Pharmaceuticals: Major NYSE 117,320.638 33.484 28.041 6.8272 2.044
Local Peer JOHNSON & JOHNSON NYSE 431,042.275 29.295 24.108 - 2.431
Local Peer PFIZER INC NYSE 240,919.469 25.054 18.213 3.4396 3.535
Local Peer MERCK & CO INC NYSE 206,407.910 29.207 37.050 6.1995 3.040
Local Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 201,399.567 24.950 22.418 3.7267 2.330
Local Peer ABBVIE INC NYSE 191,562.312 42.046 29.073 15.2408 4.460
Local Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 187,324.141 29.070 26.313 17.9170 1.273
Local Peer BRISTOL-MYERS SQUIBB CO NYSE 125,526.994 - - 3.4103 3.289
Local Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 101,691.465 13.794 17.145 4.7872 5.119
Local Peer TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS NYSE 43,733.528 12.336 10.830 0.9266 5.544
Local Peer ORGANON & CO NYSE 9,056.627 4.193 4.193 -4.6829 -
Local Peer BIOHAVEN PHARMACEUTICAL HLDG CO LTD NYSE 8,966.505 - - -19.7553 -
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 2,589.985 8.489 8.656 1.6778 -
Other Local Peers ADC THERAPEUTICS SA (NYSE), AMNEAL PHARMACEUTICALS INC (NYSE), ZYMEWORKS INC (NYSE), LANNETT CO INC (NYSE)
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 191,380.138 59.881 50.751 12.2085 1.879
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 125,260.416 8.923 18.088 1.6703 -
Global Peer WUXI APPTEC CO LTD HKEx 475,611.164 143.301 102.704 10.7734 0.218
Global Peer ROYALTY PHARMA PLC NASDAQ 22,350.001 22.922 23.005 3.8980 0.521
Global Peer VIATRIS INC NASDAQ 15,841.699 - - 0.7470 -
Global Peer REPLIGEN CORP NASDAQ 14,901.020 248.656 149.110 9.2953 -
Global Peer HANSOH PHARMACEUTICAL GROUP CO LTD HKEx 106,010.065 36.724 34.307 4.7121 0.430
Global Peer INNOVENT BIOLOGICS INC HKEx 101,734.560 - - 7.1099 -
Global Peer CANSINO BIOLOGICS INC HKEx 71,804.891 - 91.172 8.5149 -
Global Peer ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS NASDAQ 8,342.098 - - 10.2320 -
Other Global Peers LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), SINOPHARM GROUP CO. LTD. (HKEx), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), ALLAKOS INC (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO INC (HKEx), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), INNOCARE PHARMA LTD (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), NEKTAR THERAPEUTICS (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), OPKO HEALTH INC (NASDAQ), ERASCA INC (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), ATAI LIFE SCIENCES NV (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), EVEREST MEDICINES LTD (HKEx), DICERNA PHARMACEUTICALS INC. (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP LIMITED (HKEx), CSTONE PHARMACEUTICALS (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), OCUMENSION THERAPEUTICS (HKEx), NURIX THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), Y-MABS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S A (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), IMMUNOTECH BIOPHARM LTD (HKEx), OLEMA PHARMACEUTICALS INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), KINNATE BIOPHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), ATEA PHARMACEUTICALS INC (NASDAQ), Kimia Farma Tbk. (IDX), ABBISKO CAYMAN LTD (HKEx), TENAYA THERAPEUTICS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), GOSSAMER BIO INC (NASDAQ), KRONOS BIO INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), CULLINAN ONCOLOGY INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), SUTRO BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ANTENGENE CORP LTD (HKEx), MIND MEDICINE (MINDMED) INC (NASDAQ), GH RESEARCH PLC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), PETIQ INC (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), ALIGOS THERAPEUTICS INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), ANNEXON INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), VERU INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), G1 THERAPEUTICS IN (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), PHARVARIS NV (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), HUA MEDICINE (HKEx), Soho Global Health Tbk. (IDX), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), AC IMMUNE SA (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), EVOLUS INC (NASDAQ), IGBB (Bursa), WEREWOLF THERAPEUTICS INC (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), RACE ONCOLOGY LTD (ASX), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CLENE INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), STARPHARMA HOLDINGS LIMITED (ASX), SILVERBACK THERAPEUTICS INC (NASDAQ), CYBIN INC (NYSE American), CLEARSIDE BIOMEDICAL INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), FUSION PHARMACEUTICALS INC (NASDAQ), BSTEAD (Bursa), OYSTER POINT PHARMA INC (NASDAQ), NEXIMMUNE INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), ATHENEX INC (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), XOMA CORP (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), PHARMA (Bursa), DURECT CORP (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), TRICIDA INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), IMMUNIC INC (NASDAQ), OBSEVA SA (NASDAQ), ANNOVIS BIO INC (NYSE American), INOZYME PHARMA INC (NASDAQ), MUSTANG BIO INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), IP (SET), TFF PHARMACEUTICALS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), HOOKIPA PHARMA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), IX Biopharma (SGX), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), POLYPID LTD (NASDAQ), NOVAN INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), NEUBASE THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), VTV THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), KALA PHARMACEUTICALS INC (NASDAQ), NOXOPHARM LTD (ASX), APREA THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), KOTRA (Bursa), EDESA BIOTECH INC (NASDAQ), EYENOVIA INC (NASDAQ), MEDIWOUND LTD (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), GENPREX INC (NASDAQ), IMARA INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), YUMANITY THERAPEUTICS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), GALECTO INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MANNATECH INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), ELEDON PHARMACEUTICALS INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), Hyphens Pharma (SGX), NOVA (Bursa), PAK FAH YEOW INTERNATIONAL (HKEx), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), AYTU BIOPHARMA INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), ABVC BIOPHARMA INC (NASDAQ), EXOPHARM LTD (ASX), SYNAPTOGENIX INC (NASDAQ), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), INVION LTD (ASX), BIOHLDG (Bursa), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), ACURX PHARMACEUTICALS INC (NASDAQ), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), RENOVORX INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), SEQLL INC (NASDAQ), BAUDAX BIO INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), PALLA PHARMA LTD (ASX), MEDLAB CLINICAL LIMITED (ASX), PURAPHARM CORPORATION LIMITED (HKEx), ARIDIS PHARMACEUTICAL INC (NASDAQ), PHARMAXIS (ASX), CNS PHARMACEUTICALS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), XORTX THERAPEUTICS INC (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), JCT (SET), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), ONCOSIL MEDICAL LIMITED (ASX), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), SUNZEN (Bursa), TIMBER PHARMACEUTICALS INC (NYSE American), NLS PHARMACEUTICS LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), ACRUX (ASX), PAINREFORM LTD (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PETROS PHARMACEUTICALS INC (NASDAQ), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), AROVELLA THERAPEUTICS LTD (ASX), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+9.000
+3.73 %
10 Days -+13.480
+5.70 %
20 Days -+19.120
+8.28 %
Medium Term Return 3 Months -+4.840
+1.97 %
6 Months -+67.970
+37.31 %
1 Year 67.450+117.620
+139.62 %
Long Term Return 2 Years 185.755+136.220
+282.56 %
3 Years 188.253+142.310
+306.47 %
5 Years 192.530+178.060
+513.92 %
Annualised Return Annualised --
+43.75 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 129.210 - 275.870 Change From 1 Year Low +120.960 % Change From 1 Year Low (%) +93.62
Change From 1 Year High -25.700 % Change From 1 Year High (%) -9.32
2 Years Range 110.510 - 275.870 Change From 2 Years Low +139.660 % Change From 2 Years Low (%) +126.38
Change From 2 Years High -25.700 % Change From 2 Years High (%) -9.32
5 Years Range 64.180 - 275.870 Change From 5 Years Low +185.990 % Change From 5 Years Low (%) +289.79
Change From 5 Years High -25.700 % Change From 5 Years High (%) -9.32
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo.The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

Historical Price Data

Date Open High Low Close Volume VWAP
27 Oct 2021 248.610 254.460 248.320 250.170 3,180,761 -
26 Oct 2021 244.500 248.920 237.090 248.440 4,530,877 -
25 Oct 2021 244.660 246.267 240.520 245.050 2,746,439 -
22 Oct 2021 240.960 244.040 239.560 243.750 1,960,675 -
21 Oct 2021 244.950 244.950 239.834 241.170 1,717,665 -
20 Oct 2021 243.730 245.900 243.040 243.720 1,537,000 -
19 Oct 2021 239.060 242.550 239.060 242.310 1,572,841 -
18 Oct 2021 237.950 242.660 236.700 238.980 2,545,942 -
15 Oct 2021 237.420 239.299 235.820 237.880 2,598,340 -
14 Oct 2021 237.010 238.440 234.110 236.690 1,824,375 -
13 Oct 2021 234.070 237.920 232.800 236.440 2,105,586 -
12 Oct 2021 234.700 235.070 231.980 232.780 1,719,233 -
11 Oct 2021 236.700 237.990 233.600 233.670 1,892,335 -
08 Oct 2021 233.420 235.810 231.550 233.940 2,562,802 -
07 Oct 2021 229.120 234.110 229.000 233.180 2,001,776 -
06 Oct 2021 230.560 230.850 226.050 227.850 2,462,691 -
05 Oct 2021 226.440 232.560 226.175 230.930 2,793,118 -
04 Oct 2021 227.800 230.190 224.220 224.850 4,784,396 -
01 Oct 2021 231.000 231.680 225.450 229.590 2,215,667 -
30 Sep 2021 232.780 237.160 230.800 231.050 3,786,112 -
29 Sep 2021 225.410 231.440 224.560 230.360 3,970,643 -
28 Sep 2021 226.390 226.400 220.200 221.600 3,480,332 -
Summary
Current 2 Weeks
(14 Oct 2021 to 27 Oct 2021)
237.010 254.460 234.110 250.170 24,214,915 -
Previous 2 Weeks
(30 Sep 2021 to 13 Oct 2021)
232.780 254.460 230.800 236.440 26,323,716 -
4 Weeks from
(01 Sep 2021 to 29 Sep 2021)
258.540 258.770 234.110 230.360 57,196,980 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.